API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 29 days · First seen · Last updated

UK advertising regulation of weight loss medicines

Overview

The Advertising Standards Authority (ASA) has issued multiple bans against companies promoting oral weight loss medicines to the UK public.

In October 2026, the watchdog targeted several entities, including Simple Online Pharmacy, Pharmacy Online, MedExpress, Juniper, and the Care Pharmacy. The ASA ruled that Simple Online Pharmacy promoted unlicensed oral GLP-1 treatments via social media and waitlists, while Pharmacy Online was banned for promoting the oral Wegovy tablet, which is a prescription-only medicine. The regulator noted that medicinal claims cannot be made for unauthorised medicines and that consumers can identify prescription products even when direct names are not used.

By November 2026, the ASA continued its enforcement against companies such as Voy, Juniper, and MedExpress. Voy faced bans for bus and video-on-demand advertisements that used imagery and wording likely to lead consumers to believe they were seeing advertisements for licensed oral Wegovy tablets. MedExpress was also cited for using phrases like “New weight loss tablets” and “No needles” on Instagram to invite users to join waitlists. The ASA emphasized that advertisers must consider the overall impression of a campaign, as medicines do not need to be named directly to be understood as prescription-only products.

Entities

Advertising Standards Authority · Pharmacy Online · MedExpress · Wegovy · Voy

Timeline

  1. [BUSINESS] 2 sources
    UK watchdog bans weight-loss pill advertisements

    The UK's Advertising Standards Authority has banned ads from Voy, Juniper, and MedExpress for allegedly promoting prescription-only weight-loss medicines to the public.

  2. [HEALTH] 4 sources
    UK watchdog bans ads for oral weight loss medicines

    The UK's Advertising Standards Authority has banned ads for oral weight loss medicines for promoting unlicensed or prescription-only GLP-1 treatments to the public.

Sources

thegrocer.co.uk · wonderfulmalaysia.com